Acute pain following pulmonary surgery can affect the recovery process of patients. The use of intrathecal morphine (ITM) injections offers a long-lasting analgesic effect, but its clinical application remains controversial. This study aims to investigate the impact of combining bupivacaine with ITM injections on the quality of postoperative recovery in patients who have undergone pulmonary surgery.

This multicentre, randomised, double-blind, controlled trial will enrol 254 patients undergoing elective lung surgery, who will be randomly assigned in a 1:1 ratio to either group IT (receiving an intrathecal injection of 3 mg bupivacaine and 0.25 mg morphine before general anaesthesia induction) or the control group (C group). The primary outcome includes postoperative recovery quality on day 1 (quality of recovery, QoR-15), with secondary outcomes encompassing postoperative recovery quality on days 2 and 3 (QoR-15), pain scores within 72 hours postoperatively, analgesic rescue, intraoperative haemodynamic parameters, opioid consumption, postoperative adverse reactions, recovery metrics, complications, chronic pain incidence and sleep quality.

The results will be disseminated through peer-reviewed publications. This study protocol (V.2.0, 30 October 2024) involves human participants and has been approved by the Ethics Committee of Affiliated Hospital of Yangzhou University (number 2024-08-02-2), Taicang Hospital Affiliated to Soochow University (number 2025 SR-041) and Yichang Central People’s Hospital (number 2024-513-02). Each individual who agrees to participate in the research will provide written informed consent after the objectives and procedures of this study are explained to them.

ChiCTR2400092935. Registered on 26 November 2024.

To estimate tuberculosis (TB) incidence trends in the high-altitude Xizang, China, and to explore the key intervention strategies on achieving the WHO 2030 TB control target.

We developed a susceptible–exposed–infectious–recovered transmission model using routinely reported TB surveillance data from 2004 to 2022. Scenario-based simulations were conducted to project future TB incidence under alternative intervention strategies. Model assumptions are as follows: (1) a stable population, (2) lifelong vaccine-induced immunity, (3) infectiousness of active TB cases, (4) relapse risk after recovery and (5) homogeneous mixing within the population.

Seven prefectures of Xizang Autonomous Region on the Tibetan Plateau, China.

An estimated population of approximately 3 million individuals residing in Xizang.

We assessed the epidemiological impact of four interventions implemented independently: increasing vaccine efficacy rate, reducing transmission rates of susceptible individuals, decreasing progression rate from latent TB infection to active disease and reducing relapse rate among successfully treated patients, compared with continuation of current control measures.

The estimated basic reproduction number (R₀ ) for TB in Xizang was 0.39 (95% CI 0.21 to 0.71) in the absence of additional interventions, which was the highest among all regions of China. Model simulations indicated that all four evaluated interventions were each likely to reduce TB incidence, but only reducing the latent-to-active TB progression had a substantial effect. A 50% reduction in the progression rate was predicted to lower TB incidence from 66.56 (62.00–70.11) to 40.54 (37.15–43.77) cases per 100 000 population, meeting the WHO 2030 TB control target.

Targeted management of individuals with latent TB infection should be strengthened to substantially reduce TB transmission in high-altitude areas.

Postoperative acute pain following video-assisted thoracoscopic surgery (VATS) impedes patient rehabilitation. While multimodal analgesia effectively mitigates postoperative acute pain and facilitates the postoperative rehabilitation process, the efficacy of preventive precision multimodal analgesia (PPMA) remains uncertain. This study designs a PPMA strategy targeting incisional pain, inflammatory pain and visceral pain in VATS. It aims to investigate the impact of the PPMA strategy on the postoperative acute pain process and rehabilitation outcomes.

This multicentre, single-blinded, randomised controlled trial will enrol adult patients scheduled for elective thoracoscopic lobectomy or segmentectomy. A total of 1372 participants will be recruited and randomly allocated in a 1:1 ratio to either the preventive precision multimodal analgesia group (PPMA Group) or the conventional multimodal analgesia group (CMA Group). Patients in the PPMA Group will receive a regimen consisting of local anaesthetic infiltration of surgical incision (for incisional pain), intravenous injection of oxycodone (for visceral pain) and parecoxib sodium (for inflammatory pain) before surgery initiation. Patients in the CMA Group will receive the same regimen after specimen isolation. This trial will be conducted across 13 medical centres in China from 2023 to 2026. The primary outcome is the duration of postoperative acute pain. Secondary outcomes include postoperative analgesic consumption, postoperative pain scores, intraoperative haemodynamic parameters and the Indexes of Consciousness (IoC₁ and IoC₂), as well as intraoperative arterial blood gas and ventilation parameters, intraoperative dosages of general anaesthesia, inflammatory markers at predefined time points, postoperative rehabilitation process and perioperative adverse events and complications.

This study has been approved by the Ethics Committee of Xuanwu Hospital, Capital Medical University (Linyanshen[2023]-NO.012-003-Revised Vision 1). The results will be published in a peer-reviewed journal.

Chinese Clinical Trial Registry (ChiCTR2300072176).

Dementia contributes to the disease burden worldwide, and people with hypertension or type 2 diabetes are at an elevated risk of developing dementia. It is essential to prevent or delay cognitive decline in people at high risk within the community. Our trials aim to evaluate the effects of adaptive cognitive training on community-dwelling older adults with hypertension or type 2 diabetes but no dementia.

Two multicentre, double-blind, randomised, placebo-controlled trials, named COgNitive Training in community-dwelling older adults at high risk for demENTia and with Hypertension (CONTENT-Hypertension) and COgNitive Training in community-dwelling older adults at high risk for demENTia and with Diabetes (CONTENT-Diabetes), will be conducted to investigate the effects of adaptive cognitive training on participants aged 60 years or above who have been diagnosed with hypertension or type 2 diabetes but no dementia. Each trial will enrol 120 participants. Participants will be recruited from the local community in Shijingshan and Haidian Districts, Beijing, and allocated to either the intervention or control group using a 1:1 ratio. The intervention group will engage in 12 weeks of adaptive cognitive training, while the control group will receive 12 weeks of placebo cognitive training. A 24-week follow-up assessment will be conducted for all participants to evaluate the persistence of the effects. The primary outcome is the 12-week change in Montreal Cognitive Assessment (MoCA) Basic scores from baseline to the end of the intervention (12 weeks). Secondary outcomes include 6-week and 24-week changes in the MoCA from baseline; 6-week, 12-week and 24-week changes in Trail Making Test-A&B (TMT-A, TMT-B), Digit Symbol Substitution Test, the WHO/University of California at Los Angeles Auditory Verbal Learning Test and Boston Naming Test scores of cognitive functions; 6-week and 12-week changes in Geriatric Depression Scale, Generalised Anxiety Disorder-7 (GAD-7), Pittsburgh Sleep Quality Index and 12-week change in blood pressure (CONTENT-Hypertension) or fasting blood glucose and glycated haemoglobin (CONTENT-Diabetes) from baseline.

This study will adhere to the ethical principles outlined in the Declaration of Helsinki and comply with international standards for Good Clinical Practice. All participants will sign the informed consent at baseline. This study has been approved by the Ethics Committee of Plastic Surgery Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (approval numbers: 2023-139 and 2024-162). The findings of the trials will be disseminated through publications in peer-reviewed scientific journals and presented at academic conferences.

NCT06512922 and NCT06524388.

This study focused on the preferences for psychological assistance and associated factors among Chinese healthcare workers (HCWs) during the COVID-19 pandemic.

Cross-sectional analysis of survey data collected from Chinese HCWs during the COVID-19 pandemic.

Nationwide psychological service platforms in China that facilitated participation of HCWs.

A total of 901 HCWs aged 19–84 years, including doctors, nurses and other medical staff.

Preference for psychological assistance was assessed through survey options, including psychological materials, stress management skills, telephone hotline, online non-video psychological counselling, online video psychological counselling and no need or others. Prevalence of mental health symptoms was evaluated using validated scales: Patient Health Questionnaire-2 (PHQ-2) for depression, Generalised Anxiety Disorder-7 (GAD-7) and Primary Care Post-Traumatic Stress Disorder (PTSD) Screen for the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (PC-PTSD-5) for stress. Additional measures included sleep disturbance, suicidal ideation and demographic characteristics such as age, education level and occupation.

Among 901 HCWs surveyed, the prevalence of depression, anxiety and stress was 12.32% (PHQ-2 score ≥3), 42.18% (GAD-7 score ≥5) and 28.75% (PC-PTSD-5 score ≥3), respectively. Sleep disturbance and suicidal ideation were reported by 29.41% (cut-off value=2) and 9.32% (cut-off value=1) of participants. Among the 602 respondents who preferred psychological assistance, the most preferred options were stress management skills, psychological materials and online non-video counselling. HCWs with severe suicidal ideation (item 9 of PHQ-9=3) preferred online video counselling (80%). Logistic regression indicated that age was negatively correlated with the preference for psychological materials (β=–0.86, p=0.034) but positively associated with the preference of telephone hotlines (26–35 years: β=1.69, p=0.035; ≥45 years: β=1.90, p=0.031). Higher educational attainment was associated with greater preference for psychological materials (undergraduates: β=0.71, p=0.014; masters: β=1.13, p=0.007) and online counselling (masters: β=1.743, p=0.002). Nurses were more likely to prefer stress management skills (β=0.71, p=0.014), while HCWs with suicidal ideation showed a stronger preference for online video counselling (β=0.66, p

The high prevalence of mental health problems among HCWs highlights an urgent need for targeted psychological support. Distinct characteristics of HCWs were associated with different preferences for psychological assistance, highlighting the importance of tailoring interventions to the specific needs of HCWs.

Despite international efforts to address women’s long-term health and well-being, significant gaps in sexual and reproductive health (SRH) services and non-communicable diseases (NCDs) prevention remain, particularly in low-and-middle-income countries (LMICs).

We analysed data from 726 278 women aged 15–49 from six national surveys (2017–2021, Benin, Cameroon, Gabon, India, Madagascar and Mauritania) on unmet needs for NCD prevention (blood pressure, glucose, cervical cancer screening) and SRH services (contraception, antenatal, postnatal care). Unmet needs prevalence was calculated as the percentage of participants with specific unmet needs and estimated across demographics and socioeconomic groups using multivariable logistic regression models.

Unmet needs were strikingly high for NCD prevention: 36.6% for blood pressure, 70.0% for blood glucose and 98.5% for cervical cancer screening. In contrast, unmet needs for contraception, antenatal care and postnatal care were relatively lower: 7.5%, 14.5% and 14.5%, respectively. Significant variations were observed across countries. India had the lowest unmet needs for SRH services: 6.7% for contraception, 13.1% for antenatal care and 13.1% for postnatal care. Gabon had lower unmet needs for prenatal (16.8%) and postnatal care (14.8%) compared with other African countries and the lowest unmet need for cervical screening at 84.7% (95% confidential interval 83.1% to 86.2%), over 10 percentage points lower than others. Furthermore, socioeconomic factors like higher education, better economic status, healthcare access, insurance and internet use significantly lowered unmet needs, especially for antenatal and postnatal care. Employed women had higher unmet needs for antenatal (35.7%) and postnatal (37.3%) care than unemployed women (28.1%, 27.8%) but lower for NCDs prevention (98.9%, 71.8%) under two definitions than unemployed women (99.3%, 79.2%).

This study highlights the urgent need to address high unmet needs for NCD prevention among women in LMICs, particularly cervical cancer screening. Unmet SRH needs are also a major concern, given significant disparities across countries. Especially, governments should prioritise measures to focus on vulnerable groups.

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder worldwide. Although not life-threatening, its chronic and recurrent nature greatly impacts patients’ quality of life. There is strong evidence that gut-directed psychotherapies (GDPs) help improve IBS symptoms. With technological advances, digital GDP is increasingly used as an alternative to traditional face-to-face GDP. This study will compare the clinical effectiveness of digital versus face-to-face GDP for IBS through network meta-analysis.

We will search English databases (PubMed, Cochrane Library, EMBASE and Web of Science) and Chinese databases (China National Knowledge Infrastructure, Wanfang, VIP and Chinese Biomedical Database) for randomised controlled trials (RCTs) of digital or face-to-face GDP for IBS. The search will cover the period from database inception to May 2025. We will perform multivariate network meta-analyses within a frequentist framework, using the mvmeta command in STATA V.16 software, and traditional pairwise meta-analysis using the DerSimonian-Laird random-effects model. The Cochrane Risk of Bias (RoB) tool (V.2) will be used to assess the RoB of each RCT, and the Confidence in Network Meta-Analysis (CINeMA) tool will be used to evaluate the certainty of the evidence.

Ethical approval is not required for this systematic review, as it involves the collection and synthesis of data from previously published primary studies.

Open Science Framework (OSF) registration: DOI 10.17605/OSF.IO/87463.

This study aimed to evaluate the association between the stress hyperglycaemia ratio (SHR) and the Haemoglobin Glycation Index (HGI), and mortality risks in critically ill patients.

A retrospective study and machine learning (ML)-based predictive modelling.

This retrospective cohort study used data from the Medical Information Mart for Intensive Care-IV (MIMIC-IV) database.

A total of 3106 patients were included in the study and were divided into different groups according to the value level of SHR and HGI.

360-day mortality.

When treated the SHR as a continuous variable, a significant correlation exists between the SHR and 360-day mortality risks in critically ill patients (HR, 1.32; 95% CI 1.13 to 1.55). When regarded the SHR as a categorical variable, patients in the highest group were significantly associated with an increased risk of 360-day mortality compared with that of those in the lowest group (HR, 1.38; 95% CI 1.14 to 1.68). HGI, when treated as a continuous variable, was also closely associated with 360-day mortality (HR, 0.94; 95% CI 0.89 to 1.00). According to the results, the SHR index outperformed HGI at predicting all-cause 360-day mortality and adding the SHR index to the basic model for 360-day mortality improved its predictive ability (area under the curve, 0.818 for the basic model vs 0.821 for the basic model+SHR index). Furthermore, the ML-based model demonstrated the crucial contribution of SHR in predicting 360-day mortality risk of critically ill patients. Consistent with the 360-day mortality results, similar and statistically significant trends towards higher mortality at both 30 days and 90 days were observed.

SHR and HGI showed a strong association with 360-day and short-term mortality risks. The SHR index appears to be the most promising index for prevention and risk stratification in critically ill patients.

Postherpetic neuralgia (PHN) is a debilitating complication of herpes zoster (HZ) that significantly impairs quality of life, disrupting sleep, daily activities and work capacity. Globally, PHN represents a major public health challenge, with marked heterogeneity in its epidemiological patterns across different regions and demographic groups. The escalating incidence of both HZ and PHN underscores the urgent need to elucidate modifiable and non-modifiable risk factors, which is critical for implementing targeted prevention strategies and optimising therapeutic interventions. Although previous studies have examined PHN risk factors, there remains a paucity of comprehensive, up-to-date systematic analyses evaluating its global epidemiological trends and associated determinants. This protocol presents the methodology of a planned systematic review to assess an updated global estimate of PHN epidemiology and synthesises critical risk factors associated with PHN prevalence or severity.

This systematic review and meta-analysis will be conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. We will search MEDLINE/PubMed, Embase, Web of Science, CENTRAL, PsycINFO, Google Scholar, CNKI, Wanfang and CBM for English/Chinese studies published from inception through April 2025. Eligible studies will include adults (≥18 years) with HZ or PHN that report PHN prevalence/incidence or relevant risk factors (eg, age, vaccination status, acute pain severity, comorbidities). Two reviewers will independently screen records, extract data (including study characteristics, demographics, risk factors and pain metrics) and assess risk of bias using Joanna Briggs Institute tools and ROBINS-I. Random-effects meta-analyses (R V.4.0) will pool PHN prevalence (logit-transformed Wilson scores) and ORs for risk factors, with subgroup analyses by geography, income level, clinical/demographic factors. Heterogeneity (I²≥50%) will trigger meta-regression or narrative synthesis. Sensitivity analyses will address bias robustness.

Ethics committee approval is not required. The results of the review will be published through an open access journal.

CRD42024510329.

The Chinese neuroimmunological disease database (NIDBase) cohort was established to explore genetic and environmental risk factors, clinical features, multi-omics data and prognostic biomarkers. The aim is to enhance our understanding of central nervous system (CNS) demyelinating diseases. Additionally, the establishment of this cohort will address the critical issue of the lack of comprehensive genetic data and biological samples for precision diagnosis and treatment research related to neuroimmunological diseases in China.

56 hospitals in various regions of China were selected to participate in this study. The patients diagnosed with CNS demyelinating diseases were recruited, including clinically isolated syndrome (CIS), multiple sclerosis (MS), neuromyelitis optica spectrum disease (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and autoimmune glial fibrillary acidic protein astrocytopathy (GFAP-A).

At the time of patient enrolment, the clinical information is designated as baseline data. The collected baseline data include demographic information, disease history, clinical features of each demyelinating event, treatment records, standardised scales, questionnaire assessments and laboratory test results. Furthermore, biological samples, MRI and high-density electroencephalography (hd-EEG) data will be collected at baseline. All patients will be followed up at 3 months and 6 months and annually thereafter. As of December 2024, 3866 patients with CNS demyelinating diseases have been enrolled, including 84 CIS, 282 MOGAD, 1405 MS and 2095 NMOSD. Our findings indicate that CNS demyelinating diseases, particularly NMOSD, are more prevalent in women in China, with significant age differences observed among NMOSD patients compared with those with CIS, MS and MOGAD.

In future, all patients in our cohort will be followed up at 3 months and 6 months and then annually. By the end of December 2024, the database has been locked and is now being processed and analysed, while our data continue to be updated and expanded for further analysis. Both prospective and retrospective observations will be included in this study. Subsequent publications will emerge from this multicentre cohort, encompassing genomics, clinical cohort studies, hd-EEG biomarkers, imaging-based radiomics and electrical stimulation therapies.

NCT06443333.

Early detection of carotid plaque prevents stroke and myocardial infarction. Individuals with fatty liver might be at an increased risk of developing carotid plaque, yet limited access to carotid artery ultrasound underscores the need for predictive models.

We aimed to construct six predictive models for males and females separately to predict carotid plaque among individuals with fatty liver disease.

A cross-sectional study.

We included 8361 participants aged ≥40 years (4871 males; 3490 females) with fatty liver who underwent at least one health check-up between 1 January 2020 and 31 December 2023.

The sex-stratified dataset was randomly divided into 70% training and 30% internal testing datasets. With 24 potential predictors, we applied four machine learning (ML) algorithms and two conventional logistic regression (LR) models: stepwise LR and LR based on ML-selected features (LR-ML) to develop sex-specific carotid plaque prediction models. The performances were evaluated by area under the receiver operating characteristic curve (AUC), sensitivity, specificity, precision, F1-score, accuracy, calibration curve and decision curve analysis.

Carotid plaque was determined when the local carotid intima-media thickness was ≥1.5 mm in any of the arterial segments.

Four predictors (age, hypertension, total bilirubin, total cholesterol and white blood cell count) in males and three (age, systolic blood pressure and fasting blood glucose) in females were identified by consensus across the four ML algorithms and subsequently used to construct LR models. Among all 4 ML and two LR models, the gradient boosting machine model demonstrated the best overall performance in males (AUC=0.773, 95% CI 0.749 to 0.797), while the LR-ML model was optimal in females (AUC=0.817, 95% CI 0.791 to 0.843). Calibration and decision curve analyses further demonstrated satisfactory agreement and higher net benefit across sexes. Risk stratification identified distinct low-, intermediate- and high-risk groups with progressively higher observed prevalence of carotid plaque (20.25%, 48.58% and 69.41% in males; 15.28%, 50.89% and 66.56% in females).

Our findings highlight significant sex differences in practical carotid plaque prediction, providing crucial insights for public health implications in the early identification and risk assessment of carotid plaque among individuals with fatty liver.

Tongxinluo capsule (TXL) is widely used in China as an adjunctive therapy for patients with acute coronary syndromes (ACS) who underwent percutaneous coronary intervention (PCI), collectively referred to as ACS-PCI. However, current evidence on its therapeutic effects and safety remains limited and insufficiently synthesised. This review aims to evaluate the therapeutic effects and safety of adding TXL to Western medical therapy (WM) in this population.

A systematic literature search was performed in PubMed, the Cochrane Library, CNKI, VIP and Wanfang from inception to August 2024; a rapid supplemental search was conducted up to November 2025, without language restrictions, to identify randomised controlled trials (RCTs) evaluating the therapeutic effects and safety of adding TXL to WM in patients with ACS-PCI. Dichotomous outcomes were summarised using risk ratios (RRs) with 95% CIs; absolute risk reductions (ARRs) were estimated as risk differences, and corresponding numbers needed to treat (NNTs) were calculated. Continuous outcomes were summarised using mean differences (MDs) with 95% CIs. All meta-analyses were performed using a random-effects model. The included studies generally had limitations in methodological quality, heterogeneity across analyses was low to moderate and the potential for publication bias could not be excluded. The evidence certainty for each outcome was assessed using the Grading of Recommendations Assessment, Development and Evaluation approach.

Eighteen RCTs involving 1800 participants were included. Low-certainty evidence indicated that adding TXL to WM may reduce the risks of restenosis (RR=0.30, 95% CI 0.10 to 0.91; ARR=0.056, NNT=18), revascularisation (RR=0.28, 95% CI 0.10 to 0.80; ARR=0.069, NNT=15), myocardial infarction (RR=0.44, 95% CI 0.20 to 0.98; ARR=0.033, NNT=31), angina (RR=0.32, 95% CI 0.17 to 0.61; ARR=0.076, NNT=14) and other cardiovascular events (RR=0.41, 95% CI 0.24 to 0.71; ARR=0.075, NNT=14). It also improved Seattle Angina Questionnaire scores (MD=8.82, 95% CI 6.58 to 11.05) and quality of life (qualitative synthesis). However, no statistically significant reductions were observed for sudden cardiac death (RR=0.39, 95% CI 0.12 to 1.27; ARR=0.022, NNT=45), or non-cardiovascular adverse events (RR=0.67, 95% CI 0.32 to 1.40; ARR=0.043, NNT=24) when TXL was added to WM.

Current evidence suggests that adjunctive TXL may reduce key cardiovascular events and improve symptoms and quality of life in patients with ACS-PCI, without increasing the risk of non-cardiovascular adverse events. However, all findings are based on low-certainty evidence. These results provide preliminary support for the use of TXL as an adjunctive therapy, but high-quality, multicentre RCTs are needed to confirm these effects and inform clinical guidelines.

CRD42024509453.